Jacksonville hospital earns top honor for stroke care quality
Onslow Memorial has been upholding its prestigious honor of being stroke certified by making sure they are constantly meeting all the standards that help ensure quality and safety measures for all stroke care patients in the hospital.
'It does mean that we are giving that good quality of care. We also do outreach at community events, making sure that we're doing stroke screenings, making sure we're doing stroke education to the patients, making sure that they have all the tools that they need when they're discharged,' Manager of Quality Improvement & Accreditation for Onslow Memorial Takenya LaBriado said. 'So, it is a lot of care inside and outside of the hospital.'
Onslow Memorial aims to provide the highest quality evidence-based practice it can for the community and all patients who are receiving stroke care.
'It guarantees the patients that they're getting the most appropriate and latest care that they can for stroke, because stroke is a disease process,' Onslow Memorial Medical Director Terence Kolb said. 'That's certainly something we can intervene on the earlier you come, the more we can do because everything is timed and so, this is a big, important topic here in this area.'
'We want to be the community's choice for stroke care. So, you can trust us to make sure that you get all the needs that you need if you are having a stroke,' LaBriado said. 'So, you're going to get that education, you're going to get all the tools and you're going to get quality staff to take care of you.'
The certification showcases the hospital's commitment to providing the highest level of care for all stroke patients.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
9 minutes ago
- Medscape
Rapid Review Quiz: Noncolorectal Gastrointestinal Cancers
Noncolorectal gastrointestinal (GI) cancers represent a clinically significant and diverse group of malignancies impacting patient outcomes across multiple organ systems. Given the range in epidemiology, risk factors, and management strategies for these cancers, it is essential for clinicians to recognize and stay up to date on current guidelines related to their surveillance, diagnosis, and treatment. Familiarity with the evolving landscape of noncolorectal GI cancers is foundational for effective clinical decision making in everyday practice. According to current National Comprehensive Cancer Network (NCCN) guidelines, pancreatic cancer surveillance should be considered in individuals with pathogenic variants in the STK11 germline, such as Peutz-Jeghers syndrome. An expert review of the current clinical practice guidance from the American Gastroenterological Association concurs that surveillance should be considered in patients with Peutz-Jeghers syndrome or other genetic syndromes associated with an increased risk of pancreatic cancer. Having only one first-degree relative with pancreatic cancer can increase risks; however, surveillance is generally recommended only when there is a stronger family history, such ≥ 2 affected relatives (along a the first-degree relative with pancreatic cancer) or additional genetic risk factors. Although smoking is a known risk factor for pancreatic cancer, surveillance in all smokers is typically not advised. Learn more about workup for pancreatic cancer. Over the past several decades, the number of new esophageal squamous cell carcinoma cases has declined in Western nations, including the US. However, the number of new esophageal adenocarcinoma diagnoses has simultaneously risen considerably in the West. This is consistent with other epidemiological data. Esophageal squamous cell carcinoma, rather than esophageal adenocarcinoma, has been strongly linked to alcohol use. Conversely, esophageal adenocarcinoma is more strongly associated with GERD and Barrett esophagus. Of the two main types of esophageal cancer, data indicate squamous cell carcinoma generally has a poorer prognosis than adenocarcinoma. Learn more about the background of esophageal cancer. Although incidence is decreasing, hepatitis B infection remains the most common cause of HCC globally. However, MASLD has overtaken hepatitis C virus infection as the leading cause of HCC in patients listed for liver transplantation in the US. Further, one study found that MASLD represented the most common (35.6%) underlying cause of the condition. Alcohol-associated liver disease accounts for a minority of HCC cases in the US, representing up to 5.6% in recent analyses. Learn more about HCC etiology. Gallstones are an established risk factor for gallbladder carcinoma. Most cases of gallbladder cancer are adenocarcinoma rather than squamous cell carcinoma. Unfortunately, gallbladder carcinomas are usually identified at nonresectable stages , largely owing to the similarity in symptoms to more benign conditions, such as cholecystitis. Jaundice is typically an indicator of poor prognosis in gallbladder carcinoma. Learn more about deterrence/prevention of gallbladder cancer. The latest guidelines from the NCCN recommend patients with previously untreated, advanced, HER2-positive gastric cancer receive a combination of platinum- and fluoropyrimidine-based chemotherapy and HER2-targeted therapy in the form of trastuzumab as an initial therapy. Guidelines from the American Society of Clinical Oncology similarly recommend trastuzumab plus pembrolizumab in conjunction with chemotherapy that is either fluoropyrimidine- or oxaliplatin-based as an initial therapy for this population. Chemotherapy with ICI is generally indicated for HER2-negative cases, not as an initial therapy in HER2-positive cases. Chemotherapy alone is not considered optimal therapy in confirmed HER2-positive cases, and ICI monotherapy is not recommended as an initial therapy for this group. Learn more about the treatment of gastric cancer.
Bloomberg
10 minutes ago
- Bloomberg
Sarepta Needs to Show FDA Elevidys Won't Cause More Deaths
The Food and Drug Administration won't sign off on Sarepta Therapeutics Inc. bringing its controversial gene therapy back to the market until the company can persuade US regulators that it won't cause more deaths, according to an official familiar with the situation. The FDA has not seen a convincing explanation as to why Sarepta's gene therapy for Duchenne muscular dystrophy, Elevidys, was tied to two fatal cases of liver failure, the official said, and there may be no single, easily addressable problem the company can quickly fix. A third fatal case of liver failure that occurred during a trial of a separate but similar Sarepta gene therapy is unquestionably relevant information to the safety of Elevidys, said the official, who declined to be identified because the agency's deliberations are private.
New York Times
10 minutes ago
- New York Times
Texas A&M mascot Miss Reveille X undergoes surgery to remove eye diagnosed with glaucoma
Texas A&M's official mascot, Miss Reveille X, was diagnosed with glaucoma, according to a statement from Texas A&M president Mark A. Welsh III. Miss Reveille X, a rough collie, experienced 'discomfort' and 'cloudiness' in her right eye. Veterinarians at Texas A&M Veterinary Medical Teaching Hospital recommended that Miss Reveille X undergo surgery. Out of 'an abundance of caution,' her eye was removed. Advertisement 'I'm grateful to report that Miss Rev has come through the surgery successfully, has been discharged and is resting comfortably. Our priority is her health and well-being, and we are blessed to have access to the remarkably talented and caring Texas A&M veterinary team who will continue to monitor Miss Rev on her road to recovery.' Miss Reveille X became the Aggies' mascot on April 30, 2021. She, along with the past mascots, is cared for by the Corps of Cadets Company E-2. On football game days, Miss Reveille X can be seen running out on the field with her handler. The First Lady of Aggieland will take a 'brief hiatus from engagements' as she makes her recovery. 'According to her veterinary team, we can expect Miss Rev to be back to enjoying all her favorite activities — cruising on Rev Force One, attending classes, cheering on the Aggies and keeping our campus squirrels in line — this fall.'
